Zydus's Sentynl Therapeutics pediatric Menkes disease drug flagged by USFDA

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2025-10-03 10:00 GMT | Update On 2025-10-03 10:00 GMT

Solana Beach: Sentynl Therapeutics, Inc., a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences, Ltd., has announced that the U.S. Food and Drug Administration (USFDA) has issued a Complete Response Letter (CRL) relating to its New Drug Application (NDA) for copper histidinate (CUTX-101), intended to treat Menkes disease in pediatric patients.

The USFDA provided findings within the CRL that Sentynl and Zydus Lifesciences will need to address to clarify the path forward. Specifically, the USFDA mentioned a CGMP inspection of the facility where CUTX101 is manufactured. Zydus recently provided responses to USFDA’s September 2025 re-inspection demonstrating the facility’s CGMP compliance and is awaiting USFDA’s Establishment Inspection Report (EIR).

Sentynl will request a meeting with USFDA to discuss the CRL and resubmission of the CUTX-101 NDA. The CRL did not cite any other approvability concerns, nor did it identify any deficiencies in CUTX101’s efficacy and safety data.

“We recognize the USFDA’s decision and remain dedicated to working with the Agency to clarify next steps. Our commitment to patients is unchanged. We believe in the promise of our therapy and are prepared to address the feedback and pursue resubmission promptly,” said Matt Heck, CEO, Sentynl.

Menkes disease is a rare X-linked recessive pediatric genetic disease that impacts an estimated 1 in 34,810 to as high as 1 in 8,664 live male births. Patients with Menkes disease are born with the inability to absorb dietary copper and subsequently have impaired copper transport across the blood-brain barrier.

CUTX101 is a subcutaneous injectable formulation of copper histidinate that restores copper homeostasis and maintains copper levels in patients with Menkes disease. The CUTX-101 NDA was initially granted Priority Review by the FDA and is supported by positive topline clinical efficacy results for CUTX-101, demonstrating significant improvement in overall survival for Menkes disease subjects who received early treatment with CUTX-101.

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Zydus's Sentynl Therapeutics pediatric Menkes disease drug flagged by USFDA

Similar News

GSK Shingrix new prefilled syringe presentation gets positive CHMP opinion

Boehringer Ingelheim Jascayd gets nod in China for idiopathic pulmonary fibrosis

Health Ministry Proposes Barcoding Rule for All Vaccines, Antimicrobials, Anticancer, and Narcotic Drugs

Torrent Pharma Receives SEC Approval to Market Alogliptin-Metformin FDC, Asked to Conduct Phase IV Trial

Biocon Biologics Gets Health Canada Nod for Yesintek, a Biosimilar to Stelara

CDSCO Panel Seeks More Toxicity Data from Macleods on Semaglutide Injection Pre-Filled Pens

AstraZeneca Tezspire approved in EU for chronic rhinosinusitis with nasal polyps

Innovent Biologics inks Global Strategic pact with Takeda to advance next generation IO, ADC cancer therapies